Your browser doesn't support javascript.
loading
Impact of Acute Dopamine Replacement on Cognitive Function in Parkinson's Disease.
Seemiller, Joseph; Morrow, Christopher; Hinkle, Jared T; Perepezko, Kate; Kamath, Vidyulata; Pontone, Gregory M; Mills, Kelly A.
Affiliation
  • Seemiller J; Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
  • Morrow C; Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
  • Hinkle JT; Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
  • Perepezko K; National Rehabilitation Research & Training Center on Family Support, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Kamath V; Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
  • Pontone GM; Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
  • Mills KA; Department of Neurology, University of Florida College of Medicine, Gainesville, Florida, USA.
Mov Disord Clin Pract ; 11(5): 534-542, 2024 May.
Article in En | MEDLINE | ID: mdl-38470011
ABSTRACT

BACKGROUND:

PD causes striatal dopaminergic denervation in a posterior/dorsal to anterior/ventral gradient, leaving motor and associative cortico-striato-pallido-thalamic loops differentially susceptible to hyperdopaminergic effects with treatment. As the choice and titration of symptomatic PD medications are guided primarily by motor symptoms, it is important to understand their cognitive implications.

OBJECTIVE:

To investigate the effects of acute dopaminergic medication administration on executive function in Parkinson's disease (PD).

METHODS:

Participants with idiopathic PD were administered the oral Symbol Digit Modalities Test (SDMT; n = 181) and the Stroop test (n = 172) in the off-medication and "best on" medication states. ANCOVA was used to test for differences between off-medication and on-medication scores corrected for age and years of education.

RESULTS:

After administration of symptomatic medications, scores worsened on the SDMT (F = 11.70, P < 0.001, d = -0.13), improved on the Stroop color (F = 26.89, P < 0.001, d = 0.184), word (F = 6.25, P = 0.013, d = 0.09), and color-word (F = 13.22, P < 0.001, d = 0.16) test components, and the Stroop difference and ratio-based interference scores did not significantly change. Longer disease duration correlated with lower scores on the SDMT, Stroop color, word, and color-word scores; however, longer disease duration and higher levodopa-equivalents correlated with higher Stroop difference-based interference scores.

CONCLUSIONS:

Symptomatic medication differentially affects performance on two cognitive tests in PD. After acute treatment, core Stroop measures improved, Stroop interference was unchanged, and SDMT performance worsened, likely reflecting complex changes in processing speed and executive function related to acute treatment. When considering motor symptom therapies in PD, an individual's cognitive demands and expectations, especially regarding executive function, should be considered.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Parkinson Disease / Cognition / Executive Function Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Mov Disord Clin Pract / Mov. disord. clin. pract / Movement disorders clinical practice Year: 2024 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Parkinson Disease / Cognition / Executive Function Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Mov Disord Clin Pract / Mov. disord. clin. pract / Movement disorders clinical practice Year: 2024 Type: Article Affiliation country: United States